Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2505 | 0.98 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL2879833 | 0.96 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL102472 | 0.92 | POLB (0.41) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1709463 | 0.84 | OPRM1 (0.48) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1972216 | 0.84 | TSHR (0.40) | ALDH1A1TSHRMEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL1283011 | 0.82 | OPRM1 (0.47) | ALDH1A1TSHRMEN1KMT2APOLB | |
| SCHEMBL15166914 | 0.82 | POLB (0.38) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1709447 | 0.81 | OPRM1 (0.35) | SMN1; SMN2ALDH1A1TSHRKMT2AOPRM1 | |
| SCHEMBL9606533 | 0.81 | CYP1A2 (0.40) | SMN1; SMN2ALDH1A1POLBDPP4LMNA | |
| SCHEMBL31147335 | 0.80 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1TSHRKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163074-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2025-05-22 | — | — | US | disclosed |
| US-12129262-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-10-29 | — | — | US | disclosed |
| CN-116940563-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220267345-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-08-25 | — | — | US | disclosed |
| EP-1856110-B1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-7671080-B2 | 1-benzylindole-2-carboxamide derivatives | N.V. ORGANON (NL) | 2010-03-02 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20060194842-A1 | Oxyindole derivatives | PFIZER INC. | 2006-08-31 | — | — | US | disclosed |
| US-20020128185-A1 | Pharmaceutical compounds | HAWAII, UNIVERSITY OF | 2002-09-12 | — | — | US | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5955487-A | TREATING HIGH BLOOD PRESSURE, CARDIAC INSUFFICIENCY, GLAUCOMA | CIBA-GEIGY CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| US-5620998-A | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| US-5559233-A | 3-/P-PHENYLBENZYL/IMIDAZOLONES AND PYRIMIDONES | SANOFI (FR) | 1996-09-24 | — | — | US | disclosed |
| US-5506240-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| US-5352788-A | Angiotensin antagonist | ELF SANOFI (FR) | 1994-10-04 | — | — | US | disclosed |
| US-5270317-A | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1993-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267345-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | SMN1; SMN2 1955/4885ALDH1A1 2921/4885TSHR 3775/4885 |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | SMN1; SMN2 3385/4885ALDH1A1 2904/4885TSHR 3916/4885 |
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | HTR4, HTR5A, HRH4 | SMN1; SMN2 326/4885ALDH1A1 2553/4885TSHR 716/4885 |
| US-20250163074-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | SMN1; SMN2 1955/4885ALDH1A1 2921/4885TSHR 3775/4885 |
| US-20020128185-A1 | Pharmaceutical compounds | XPO5, XPOT, XPO1 | SMN1; SMN2 2941/4885ALDH1A1 4250/4885TSHR 4372/4885 |
| US-20060194842-A1 | Oxyindole derivatives | HTR4, HTR5A, HRH4 | SMN1; SMN2 326/4885ALDH1A1 2553/4885TSHR 716/4885 |
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | SMN1; SMN2 3331/4885ALDH1A1 858/4885TSHR 247/4885 |
| US-12129262-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | SMN1; SMN2 1955/4885ALDH1A1 2921/4885TSHR 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.